RxDoctor Payments DataLook up a doctor →

Jamie Larson

Family · Toms River, NJNPI 1184960395

Payments from drug & device makers

$9,614in general payments, 2019–2025

Across 607 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • AbbVie$842
  • Amgen$764
  • GSK$762
  • Pfizer$760
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$9,51599%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,614 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$61,111
Medicare patients
174
Services billed
836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$82,133
JardianceEmpagliflozin30$31,625
FarxigaDapagliflozin Propanediol15$20,303
JanuviaSitagliptin Phosphate13$18,320
Bydureon BciseExenatide Microspheres14$17,057
Breo ElliptaFluticasone/Vilanterol15$6,521
Albuterol Sulfate HfaAlbuterol Sulfate82$2,542
Rosuvastatin Calcium174$2,432
Atorvastatin Calcium141$1,759
Levothyroxine Sodium118$1,353
Ventolin HfaAlbuterol Sulfate19$1,083
Escitalopram Oxalate39$918
Pravastatin Sodium38$914
Valsartan11$817
Ezetimibe14$660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,562$82,13343 claims
Boehringer IngelheimJardiance$604$31,62530 claims
AstraZenecaFarxiga$1,452$20,30315 claims
MerckJanuvia$68$18,32013 claims
GSKBreo Ellipta$762$6,52115 claims
AbbVieSynthroid$842$63619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.

Other family in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →